Sigrima 420Mg Inj

Name: Sigrima 420Mg Inj
Brand: ONCOTRUST
Price: 50000.0 INR
Availability: InStock

Price 50000.0 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

Sigrima 420Mg Inj Specification

Indication
Anemia associated with chronic renal failure and chemotherapy

Salt Composition
Recombinant Human Erythropoietin Alfa (420 mcg) (as lyophilized powder)

Dosage Form
Injection

Enzyme Types
Erythropoiesis-Stimulating Agent (ESA)

Feature
High purity, sterile, ready-to-use injection

Ingredients
Recombinant Erythropoietin Alpha, excipients

Application
Used to stimulate red blood cell production in patients with anemia

Ph Level
Between 6.5 and 7.5

Temperature Needed For Fermentation
rankine Rankine

Physical Color/Texture
Yellowish Powder

Fermentation Smell
Normal Smell

Enzymatic Activity
Stimulates erythroid progenitor cells in bone marrow

Storage Instructions
Store at 2C to 8C. Do not freeze.

Shelf Life
24 Hours

Route of Administration
Intravenous or Subcutaneous

Container Type
Glass vial and ampoule

Molecular Weight
Approximately 30,400 Daltons

Volume
As per label after reconstitution

Reconstitution
Requires reconstitution with sterile water for injection

Market Authorization
Prescription only

Packaging Type
Single-use glass vial with solvent ampoule

Contraindications
Uncontrolled hypertension, known hypersensitivity to EPO or excipients

Primary Use
Treatment of anemia in chronic kidney disease and cancer patients

Sterility
Sterile, pyrogen-free

Sigrima 420Mg Inj Trade Information

Minimum Order Quantity
1 Piece

Delivery Time
24 Hours

About Sigrima 420Mg Inj

Pertuzumab Injection is a targeted monoclonal antibody used in the treatment of HER2-positive breast cancer. It works by binding to the HER2 receptor on cancer cells, inhibiting cell growth and preventing tumor progression. Pertuzumab is commonly administered in combination with Trastuzumab and chemotherapy to enhance therapeutic effectiveness in both early and metastatic breast cancer cases. Composition:Pertuzumab (Recombinant Humanized Monoclonal Antibody) Indications: HER2-positive breast cancer Metastatic breast cancer Neoadjuvant and adjuvant breast cancer therapy Mechanism of Action:Pertuzumab blocks the dimerization of the HER2 receptor with other HER family receptors, thereby interrupting cancer cell signaling pathways and slowing tumor growth. Dosage & Administration: Administered intravenously (IV infusion) Dosage as prescribed by a qualified oncologist Used in combination therapy as per clinical protocol Storage Instructions: Store at 2C to 8C Do not freeze Protect from light Precautions: To be administered under medical supervision only Monitor cardiac function during treatment Not recommended for pregnant or breastfeeding women unless advised by a physician Packaging:Vial / Injection (strength as per availability) Quality Assurance: WHO-GMP certified manufacturing Stringent quality control and safe packaging

Indication and Key Benefits

Sigrima 420Mg Inj is primarily used to treat anemia in patients with chronic kidney disease or undergoing chemotherapy. By stimulating erythropoiesis, it effectively increases red blood cell counts, helping alleviate symptoms of anemia such as fatigue and weakness. Regular therapeutic use improves patient quality of life and reduces the need for blood transfusions.

How to Prepare and Use

The product comes as a lyophilized yellowish powder in a sterile glass vial, accompanied by a solvent ampoule. Before administration, the powder must be reconstituted with sterile water for injection. Intravenous or subcutaneous injection can be used, as prescribed by a healthcare professional. Dosage and administration frequency depend on the individual patient's condition and response to treatment.

Storage and Handling Guidelines

To ensure efficacy and safety, Sigrima 420Mg Inj must be stored between 2C and 8C. Avoid freezing the product. Use the reconstituted solution within the recommended timeframe as per the label instructions. Proper handling and storage maintain the injection's high purity and activity profile.

FAQ's of Sigrima 420Mg Inj:

Q: How should Sigrima 420Mg Inj be reconstituted before administration?

A: Sigrima 420Mg Inj must be reconstituted with the provided sterile water for injection from the ampoule. Mix gently without shaking, and use the resulting solution as directed in the label for intravenous or subcutaneous administration.

Q: What is the main benefit of using Sigrima 420Mg Inj in cancer and kidney disease patients?

A: This injection significantly reduces anemia by stimulating red blood cell production, which can decrease fatigue and improve overall well-being in patients with chronic kidney disease or those receiving chemotherapy.

Q: When is it appropriate to use Sigrima 420Mg Inj?

A: Sigrima 420Mg Inj is indicated when anemia is diagnosed in patients with chronic kidney disease or as a complication of chemotherapy, provided the patient does not have contraindications such as uncontrolled hypertension or hypersensitivity to erythropoietin.

Q: Where should Sigrima 420Mg Inj be stored to ensure stability?

A: Store the vials and solvent ampoules at a temperature between 2C and 8C. Always keep the product away from direct light and never freeze it. Use within 24 hours after reconstitution if not administered immediately.

Q: What precautions should be taken during the administration process?

A: Administration must be performed under medical supervision. Check for signs of hypersensitivity or uncontrolled hypertension, and follow aseptic techniques to maintain sterility. Ensure the solution is clear and free from particles before injection.

Q: How does Sigrima 420Mg Inj work to treat anemia?

A: This medication acts as an erythropoiesis-stimulating agent by activating erythroid progenitor cells in the bone marrow, increasing the production of functional red blood cells.

Tell us about your requirement